Streptococcus pneumoniae non-susceptibility and outpatient antimicrobial prescribing rates at the Alaska Native Medical Center

Figures & data

Table I. Minimum inhibitory concentration (MIC) endpoints used in this study (17)

Antimicrobial agent	Susceptible	Intermediate	Resistant
Penicillin	≤2	4	≥8
Cefotaxime/ceftriaxone	≤1	2	≥4
Tetracycline	≤2	4	≥8
Erythromycin	≤0.25	0.5	≥1
Trimethoprim/sulfamethoxazole	≤0.5	1–2	≥4

Fig. 1.  Total antibiotic usage (Ceph+PCN+TET+macrolides+TMP/SMX) American Indian/Alaska Native persons ≥5 years of age (1992–2009).

Fig. 2.  Trimethoprim/sulfamethoxazole prescription rate per 1,000 American Indian/Alaska Native persons ≥5 years of age (1992–2009).

Fig. 3.  TMP/SMX non-susceptibility in IPD isolates (non-PCV7 serotypes) from patients ≥5 years of age (1992–2009).

Fig. 4.  Macrolide prescription rate per 1,000 American Indian/Alaska Native persons ≥5 years of age (1992–2009).

Fig. 5.  Erythromycin non-susceptibility in IPD isolates (non-PCV7 serotypes) from patients ≥5 years of age (1992–2009).

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S10. 2000; Wayne, PA: National Committee for Clinical Laboratory Standards.

 Google Scholar